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ofresponders and nonresponders, andMCP'sformultiple end points.
Introduction
Why isitthatmultiple comparisonprocedures (MCPs) arebe-
ingdiscussedintoxicology eventoday,despitethefactthatthey
areevery-day proceduresinbiostatistics? This paperdealswith
several sourcesofmultiplicity inlong-termtoxicity studiesand
possible methods for suitable statistical analysis.
Based ontheclosedtestingprinciplediscussedby Marcus et
al. (1), a revolution in MCPs has taken place. We can thus
diminish the antagonism enforcing aexp (type I error) and
decreasing the power r (where ir = 1 - 3, ... type II error).
This paper presents a special case where as is held and the
maximum power of the two-sample case is guaranteed. This
paperisthereforelimitedtoregulatorytoxicitystudies, e.g., car-
cinogenicity, mutagenicity, according tonational/international
guidelines, for example, the European Community (EC)
guideline (2). Regulatory toxicity studies are so-called safety
studies, the purpose of which is to ascertain carcinogenic,
mutagenic side effects etc. For this purpose, the statistical
hypothesis inrelation totypeIand II errorsshouldbespecified:
a) The risk ofa type I error, a, represents theproducer's risk:
theconclusionisthereforethat atoxicsideeffectexists, whilein
factthisisnotthecase. b)TheriskofatypeI error, (3, represents
thecustomer's risk: theconclusionistherefore thatatoxiceffect
does notexist, while intruth oneactuallydoes. Intuitively, itis
clearthatbothrisksmustbehandledwithcare, eventhoughcon-
trolling the type II error should be of primary concern in
toxicology.
Usually, the type H error is definedcomparisonwise andthe
type I error experimentwise (am). A typical design analyses
comparisons between the control and treatment/dose groups,
several timepoints, both sexes, elements ofa multivariate end
pointvector, andmultipletumorsites. Becauseofadramaticin-
creaseinthetype II errorwithsuch ahigh-dimensionaldesign,
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ana,,p formulation is normally used forthe subdesign control
versus k treatment/dose groups. The purpose ofan adequate
statisticalanalysisistominimizethetypeIIerrorwhileholding
crexp constant. This article will therefore investigate several
MCPstoestablishtheconditionsunderwhichtheaboverequire-
mentcanbefulfilled.




subdesign. a) Control, dose,, . . ., dose,, where C = 0 < DI
< ... < D*, thepurposeofwhichistoanalyzedoseresponse
analysis or estimate the no-observed-effect dose. b) Control,
treatment, . . ., treatment*, with treatment Tj ... several sub-
stances, combinations, etc. The purpose is to characterize all
contrasts [control versus Tj Vft (1, . . ., k)J c) Control, [D>or
Tj}, P+. Thepurpose ofusing apositive control group, P+ (ad-
ministrationofaknowntoxic substance), istocheckthesensi-
tivityofthetestsystemcurrently inuse(animals, bacteria, etc.).
Usingthis simpleclosedtestingprocedure, aspcanalsobeheld






e.g., fortheAMESassayaccordingtoMargolinetal. (3); and
MCPs. Thispaperonly discusses MCPs.
MCPs are suitable for all three above-mentioned types of
design. Modeling is sometimes uncertain for the typical
guideline-relatedtwoorthreedose-groupsdesign. MCPsusually
usefewerapriorassumptions(e.g., noproblemswithacorrect




vantages, such as no possibility ofextrapolation.
MCPs in Control versus kTreatment/
Dose Groups Design
Two-Sample versusk-SampleTesting
Toxicology journals often contain papers in which the
statistical analysis is based on the two-sample t-test or the
Wilcoxon-Mann-Whitney Utest, eveninthek-samplemany-to-
one situation (4) using a comparisonwise aXcomp level; i.e.,
testing each contrast with a for example on a 0.05 level in-
dependently. Using this simple approach, the experimentwise
aexp-level isviolatedontheonehand,whereas, ontheother, the
typeIIerrorissmallerincomparisonwithanMCPanddoes not
depend on the number of treatment/dose groups. This is the
testing dilemma always faced in toxicity studies. Several com-
promises and an ideal situation (minimum type II error and
holding texp) will now bediscussed.
Many-to-one MCPs canberecommended onthewhole. But
iftwo-sample tests are used, then they should be used only for
thecontrasts (C - D,), butnotforthebetween-dosecontrasts,
(Dj-Di) with (i #j) e- (1, . . ., k).
k-Sample Tests versusk-Sample Procedures
Thereis somedesiretoclarifythedifferencebetweentestsand
MCPs frombothatoxicological andabiostatistical viewpoint.
Ak-sampletest, e.g., thewell-knownF-test, represents asingle
decision problem:
HO: FC = FD1 *-- FDk
HA:FC 7AFD1#.-.FDk
withFdistribution function fortesting theglobalsubstanceef-
fect. An MCP represents amultiple decisionproblem:
HA: Fi i4 Fj V (i 96j) e (1 .,k)
fortesting every contrast(C - Dj) Vje(1,..., k). Because not
only theglobaleffect, butalsoeachsingle contrast(C - D>) is
ofinterest intoxicology, applicationofMCPisrecommended.
A combination ofboth approaches based on theclosedtesting
principle is also possible, providing both global and local
information.
All-Pair versusMany-to-OneProcedures
Commonly used statistical software packages are generally
oriented toall-pairMCPs, suchasTukey, Scheffe,Duncan, etc.
All-pairMCPsanalyzenotonly contrastsofinterests(C - Dj)
butalsocontrasts(Dj- Di) with(i *j) E (1, . . . ,k). Thetype
IIerrorratethusincreases(S): controlversusk=3dosegroups,
afexp = 0.05, aud = 1.0; nj = 24 (with a end point-specific
variance, ddetectabledifference); many-to-oneMCP(Dunnett)




is commonly used to approximate normally distributed end
points. Othertypesofendpointsoccurringintoxicologywillnot
be discussed in this paper. For dichotomous end points, see
Piegorsch (7).
Hypothesis formulation:
HO w oC l AToi iea, wt... e c k)
HA : 4C < kzTj
without limitation, for a one-sided increase, with jtj expected
value.
Test statistics:
di = ( -xc)/VMQa(1/nc + i/nj)
withMQRthe mean-square-error estimator.
Decision rule: Howill be rejected if:
d; > dkdficj1-aone-sided
with df = Ek C(nj-k1) j e (C, 1, *--,k)
ci=i/Vnc/nj+l








n. = Vknj(14-16). ThisisnotthecasefortheWilliams (17)pro-
cedure, assuming anordered alternative (18).
Thepowerdependsonthenumberoftreatmentordosegroups
k, which implies that inclusion offurther nonsignificant treat-




notrobust (12). Otherapproaches shouldbe used in this case,
e.g., e-adjusted Welch-tests or Brownie (20) type of control




The closed testing principle in many-to-one MCPs is quite
simple(incomparisonwithall-pairMCPs)becauseacomplete






sampletests, b) sequential rejection modificationaccording to
Marcusetal. (1)orHayterandTamhane(23), c)Hommel (24,
25)/Hochberg (26) / Rom(27) reverse Holmprocedure based
ontwo-sampletests, d)closedtestingprocedurebasedonglobal
tests (5), e) procedure with a prioi hierarchical hypotheses
(28).
Bonferroni/Holm Procedure. Usespecifictwo-sampletests
for the elementary contrasts, (C - D>), Order the related
p-values:
Pj: P(1) < P(2) ,-*,.P(k)
Decision scheme: if
P(1) > a/k = 4 > STOP H(1) ...,H(k)
cannot be rejected, otherwise go tothe next step: if
P(2) > a/(k - 1) ==>
STOP H(1) H(2), H(k) A 0 0
is valid andHo(2) ..., Ho(') cannotbe rejected, etc.
Marcus etal. Modification. Use the Dunnett statistics:
VjE(i,...,k)
d; = (Rj -Rc)/ MQa(i/nc + I/nj)
Orderthe test statistics:
d(l) < d(2) <, ...-, < dtk)
Decision scheme: if
d(k) < dkdfcj,-a one-sided >
STOP H( l) ..IH(k) 0 0
cannotberejected, otherwise go tothe next step.
d(k-1) < dk-.1df~cji1-aone-sided >
STOP H(k) H(k_')
is valid andHo(l), ...,Ho(K1) cannotberejected, etc.
HochbergModification. The Hochberg modification is the
numericallysimplestversion. Usespecifictwo-sampletestsfor
theelementary contrasts, (C - D>), Ordertherelatedp-values:
Pj : P(1) < P(2) <,*X< P(kc
Decision scheme: if
P(k) <a ==> all H(). IH(k)
arerejectedandSTOP, otherwiseHo(k)isvalidandgotothenext
step. If
Pk-1) < a/2 ==> all Hl),... H(k1)
H(k-1) 0
are rejected and STOP, otherwise Ho(k-)is valid and go to the
next step, etc.
The importantdifferencebetween these three modifications
is that the Marcus et al. modification is based on an MCP and
causesadimensionreductionink, whiletheothersarebasedon
two-sampletests and cause anca reduction
Holm Modification andClosed TestingProcedure. For the
Holmmodification: thefirststepispmin versus a/k, incontrast
totheHochbergmodification, wherethefirststepisp.< versus
a. The Holmmodification is more powerful.
The closed testing procedure is based on a global test. Use
suitablej-dimensional many-to-oneteststatistics E (1, . . ., k),
e.g., Fligner/Wolfe contrasttest(29). Thetestingstrategy (for
simplicity, given here as C, k = 3) is shown in Figure 1. This
multipleprocedureworkssimplyas follows: Alevelatestisper-
formed on stage 1. Ifandonly iftheHo9e1 is rejected, all sub-
hypothesesatstage2aretestedonthesamealevel,andsoon. If
aHo( )is notrejected, noneofthe subhypotheses arerejected.
Procedure with a priori Hierarchical Hypotheses. Use
specific two-sample tests for the elementary contrasts, (C -
Dj), and estimate the relatedp-values (without ordering).
Decision scheme: if
Pk > cc ==> STOP HI,..,Hk
cannotberejected, otherwiseHo is rejected, andgotothedose
level (k-1). If
Pk-i > a ==> STOP Hl,...Hk-l
cannot be rejected, otherwiseHo(kl) is rejected, and go to the
dose level (k-2), etc.
Thisprocedurerepresents aspecialcaseoftheclosedtesting
procedure under the assumption of an ordered alternative
hypothesis. IfthePivalues withinarealstudy areordered, then
withthisprocedurewefindanideal situation inMCP: holding
Stage 1 | -(DIID2,D3)
Stage 2 C-(DD) C-(DID3) C-(D2,D3)
Stage - C-D2 3
FIGURE 1: Completehypothesessystem inthecaseofacontrolandthreedose
groups.
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ahexp and guaranteeing the maximum powers irj ofthe two-
sample tests (based on comparisonwise a). This procedure is




Now we will considerthedesign C,Di, ... , Dk. Assuminga
monotonicdependenceoftheeffectondose, restrictionofalter-
native hypotheses is possible:
HA:FC < FD1 < .. < FDk
at least Fc < FDk
Withthisrestriction, anincreaseinpowerinrelationtotheMCPs
withunrestrictedalternativehypothesescanbeexpected. Possi-
bleMCPsarea) simultaneous MCPs: forcontinuous, normal-
lydistributedendpoints, theanalogueofDunnett's MCPisthe
Williams (17,30) procedure. For the nonparametric case, the
analogueofSteel's MCPistheShirley(31,32 )procedure. b) se-
quential rejection MCPs: MCPonaprioriorderedhypotheses,
based on any two-sample tests. Forbinomially distributed end
points, theclosedtestingprocedureisbasedonArmitage's (33)
trend test (19). For Poisson-distributed end points, the closed
testing procedure is basedon Lee's (34) trend test (19).
Comparison ofSeveral Procedures with
Simulation Studies
Forcommonlyobservedconditionsofrealtoxicitystudydata,
namely expectedvalueprofiles, dimensionofk, sample sizesnj,
a levels, variances, etc., several procedures wereinvestigated
with simulation studies (5,18,28,30, 35-37). Forpractical ap-
plication, thesesimulationresultscanbesummarizedinarather
simpleway: recommendation ofthe Hommel (24) /Hochberg
(26)procedure, withoutrestrictionofthealternativehypothesis,
a power behavior near the MCPs with ordered alternative was




and ris the proportion ofresponders.
Two types of Lehmann (40) alternative will be considered
here: shift:
Fpatho(x) = Fc(x-6)
according to Good (41) andpower:
Fpatho(X) = Fa(X)
according to Lehmann (40). Johnsonetal. (42) suggested, for
theshiftalternative, approximatescorestatisticsbasedonfollow-
ing mixed normal score function:
sm(i)
= exp(-d2/2)exp(d&V(i/(nC + llT + 1))
whereiisarankinthecombined (control+treatment) sample,
disaconstant(inthesimulationstudywhered=0.5,1,1.5,2were
used; only the case d=l will be reported here), and 4-' is a
distribution functionofthenormal distribution.
As a generalization of Wilcoxon-Mann-Whitney (WMW)
scores, Conoverand Salsburg (43)proposedthefollowing ap-
proximate score functionforthepower alternative:
sc(i) = (i/(nc + nT + 1))a-1
where a is an integer constant (a=3,4,5,6 were used in the
simulation study; here, only the casea=4 will bereported).
Intoxicology, testsbasedonthismixingdistributionassump-
tionwereusedforbehavioral studies (44), teratological studies
(45), sister chromatid exchange mutagenicity assays (42),
chronicstudies(5), andmicronucleusmutagenicityassays(46).
With simulation studies (42, 46), advantages in power can be
shown for several practical data situations intoxicology.
Many-io-uneMursTormuiiipie UnimodalversusMixingDistributionAssumption End Points
All MCPs discussed in the preceding sections compare ex-
pected values. In real data, two situations may occur: greater
variability (variance) withincreasing responseandexistenceof
asubpopulationofnonresponders. Thisproblem canbetreated
by several approaches: a) use ofMCPs that are robust under
varianceheterogenicity (Hothorn andOrtseifeninpreparation);
b)so-calledlocation-scalemodels, e.g., acombinationoftheU-
test (location) andAnsari/Bradley (38) test [scale(39)] orthe
Brownie (20) type of control group variance includion; c)
assumption of a mixing distribution of responders and
nonresponders with the following hypotheses:
HO FC(x) = FD(X)
HA : FC(X) < FD(X) with FD(X)
= (1- r)Fc(x) + rFpatho(x)
In long-term toxicity studies, several endpointsoccur, (19):
approximate, normally distributed (e.g., body mass); non-
normallydistributed [e.g., theskeweddistributedliverenzyme
ASAT (5)]; binomiallydistributed (e.g., tumor rate); Poisson-
distributed (e.g., number of tumors). The commonly used
evaluationconsistsofseparateunivariateanalysisofeachsingle
endpoint, e.g., Unkelbachetal. (47),butamultivariateanalysis
ofmultipleendpointsinthemany-to-onedesignisalsopossible:
a) T2 modification according to Higazi and Dayton (48), b)
withbetterpowerbehaviorforthetypicalone-sidedhypothesis:
multipleendpointanalysis (49)basedonDunnett'sprocedure
(50) is a special case ofparametric testing after k-ranking
transformation. Both approacheshave, however, amajordisad-
vantage: onlydecisionoftheglobalendpointvector. Informa-
tion is not available on the combinations ofend points, which
mightgo as farasthe singleendpointcase.
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x'.x x3 X'I.X3.X4 x.3.x XI x2.x4
x2.x4 x'x2 .x3 x1.x4 X x
X1 [I<X4
0 H'1) rejected
FIGURE2. Complete hypotheses system inthecase offourendpoints.
The multivariate problem also consists of a complete
hypothesis system of2k - 1 elementary hypotheses (21). The
decision schemeisquitesimple (51), ascanbe seenforthefour
endpoints inFigure2. Basedonthelevel a-testoneachstep, this







With this approach, decisions can be performed both on the
multiple endpoints andthemultipledosegroupbasedonlevel
a tests on each step, butholdingac,,p (50).
Summary
This paper reveals several sources ofmultiplicity within long-
termtoxicitystudiesandtheirsuitabletreatment, thepossibility
ofreducing the antagonism between holding aspand ensuring
themaximumpower, thatspecial MCPsforbiostatisticalanalysis
oflong-termtoxicological studiesarenecessaryandareavailable
as a PC program.
REFERENCES
1. Marcus, R., Peritz, E., andGabriel, K. R. Onclosedtestingprocedurewith
specialreferencetoorderedanalysisofvariance. Biometrika63:655-660
(1976).
2. Anonymous. Empfehlungendesratesvom26.11.1983 zudenVersuchen mit
ArzneimittelspezialitaetenimHinblickaufderenInverkehrbringung(EWG
83/571). Pharmazeut. Ind. 45:1248-1261 (1983).
3. Margolin, B. H., Kaplan, N.,andZeiger, E. StatisticalanalysisoftheAmes
Salmonella/microsome test. Proc. Nadl. Acad. Sci. U.S.A. 78: 3779-3783
(1981).
4. Jossan, S. S. MPTPtoxicity inrelationtoage,dopaniineuptakeandMCA-B
activity intwo rodent species. Pharmacol. Toxicol. 64: 314-318 (1989).
5. Hothorn, L. General principles in testing of toxicological studies. In:
Statisticalmethodsintoxicology. LectureNotesinMedicalInformatics, vol.
43 (Hothorn, L., Ed.), Sprinter-Verlag, Heidelberg, 1991, pp. 111-131.
6. Dunnett, C. W. Amultiple comparisonprocedure forcomparing several
treatments with acontrol. J. Am Stat. Assoc. 50: 1096-1121 (1955).
7. Piegorsch, W. W. Multiple comparisons for analyzing dichotomous
response. Biometrics 47: 45-52 (1991).
8. Dunnett, C. W. New tables for multiple comparisons with a control.
Biometrics 20: 560-572 (1964).
9. Gupta, S. S. Onthedistributionofthestudentizedmaximumofequally cor-
related normal variables. Commun. Stat. B14: 103-135 (1985).
10. Bechhofer, R. E., and Dunnett, C. W. Tables of percentage points of
multivariatetdistributions. In: SelectedTablesinMathematical Statistics,
No. 11. American Mathematics Society, Providence, RI, 1988, pp. 1-112.
11. Ahner, C., andPassing, H. Berechnungdermultivariatent-Verteilung and
simultane Vergleiche gegen Kontrolle bei ungleichenGruppenbesetzungen.
EDV Med. Biol. 14: 113-120. (1983).
12. Rudolph, P.E. Robustnessofmultiplecomparisonprocedures: treatment
versus control. Biometrics J. 30: 41-45 (1988).
13. Steel, R. G. D. Amultiplecomparison ranksumtesttreatmentversuscon-
trol. Biometrika 15:560-572 (1959).
14. Horn, M. Regardingtheoptimalityofthe formulanjn = fortheratio
ofsamplesizesofacontrolandptreatedgroups. BiometricsJ. 21: 407-412
(1979).
15. Hochberg, Y., andlinhane, A. C. MultipleComparisonProcedures. Wiley
SeriesinProbability andMathematical Statistics. JohnWileyandSons, New
York, 1987.
16. Spurrier, J. D., and Nizam, A. Samplesizeallocationforsimultaneous in-
ference incomparison withcontrol experiments. J. Am. Stat. Assoc. 85:
181-186 (1990).
17. Williams, D. A. A test for differences between treatment means when
severaldoselevelsarecompared withazerodosecontrol. Biometrics 27:
103-117 (1971).
18. Hothorn, L. Robustness studyonWilliams-andShirley-procedure, with
application intoxicology. Biometrics J. 31: 891-903 (1989).
19. Hothorn, L. Biometrische Analyse spezieller Untersuchungen der
regulatorischen Toxikologie. In: Aktuelle ProblemederTbxikologie, Vol.
5GrundlagenderStatistikfuerToxikologen(M. HornandL. Hothorn, Eds.
Verlag Gesundheit Gmbh, Berlin, 1990, pp. 130-236.
20. Brownie, C., Boos, D. D., and Hughes-Oliver, J. Modifying the t and
ANOVA Ftest when treatment isexpected to increase variability relative
tocontrols. Biometrics46: 259-266 (1990).
21. Sonnemann, E. Allgemeine Loesung multiplierTestprobleme. EDV Med.
Biol. 3: 120-128 (1982).
22. Holm, S. Asimple sequentially rejectivemultiple testprocedure. Scand.
J. Stat. 6: 65-70 (1979).
23. Hayter, A.J.,andTamhane,A. C. Samplesizedeterminationforstep-down
multipletestprocedures: orthogonalcontrastsandcomparisonwithacon-
trol. J. Stat. Plan. Infer. 27: 271-290 (1991).
24. Hommel, G. A stagewise rejective multiple test procedure based on a
modified Bonferroni test. Biometrika 75: 383-386 (1988).
25. Hommel, G. A comparison of two modified Bonferroni procedures.
Biometrika76: 624-625 (1989).
26. Hochberg, Y. A sharper Bonferroni procedure for multiple tests of
significance. Biometrika 75: 800-802 (1988).
27. Rom, D. AsequentiallyrejectivetestprocedurebasedonamodifiedBonfer-
roni inequality. Biometrika77: 663-665 (1990).
28. Hothorn, L.,andLehmacher,W. Asimpletestingprocedure 'controlversis
k treatments' forone-sided ordered alternatives, withapplication in tox-
icology. Biometrics J. 33: 179-189 (1991).
29. Fligner, M. A., and Wolfe, D. A. Distribution-free tests for comparing
several treatments with acontrol. Stat. Neerl. 36: 119-127 (1982).
30. Wllliams, D. A. Thecomparisonofseveraldoselevelswithazerodosecon-
trol. Biometrics 28: 519-531 (1972).
31. Shirley, E. A. C. A non-parametric equivalent ofWilliams test for con-
tastinginceasingdoselevelsofatreatment. Biometrics33:386-389(1977).
32. Williams, D. A. A note on Shirley's non-parametric test for comparing
severaldoselevelswithazero-dosecontrol. Biometrics42: 183-186(1986).
33. Armitage, P. Tests forlineartrends inproportions and frequencies. Bio-
metrics II: 375-386 (1955).
34. Lee, Y. J. Tests in trends in Poisson means. J. Qual. Technol. 17: 44-49
(1985).
35. Shirley, E. A. C. Thecomparisonoftreatmentwithcontrol group means
intoxicological studies. Appl. Stat. 28: 144-151. (1979).
36. Mukerjee, H., Robertson, T., and Wright, F. T. Comparison ofseveral
treatmentswithacontrolusingmultiplecontrasts. J. AmStat. Assoc. 82:
902-910(1987).38 L. HOTHORN
37. Ruberg, S. J. Contrasts foridentifyingtheminimumeffectivedose. J. Am.
Stat. Assoc. 84:P 816-822 (1989).
38. Ansari, A. R., and Bradley, R. A. Rank-sum tests fordispersions. Ann.
Math. Stat. 31: 1174-1189 (1960).
39. Lepage, Y. A combination ofWilcoxon's and Ansari-Bradley's statistics.
Biometrika 58: 213-217 (1971).
40. Lehmann, E. L. Thepowerofranktests. Ann. Math. Stat. 24:23-43(1953).
41. Good, P. I. Detectionofatreatmenteffectwhennotallexperimental sub-
jects will respond to treatment. Biometrics 35: 483-489 (1979).
42. Johnson. R. A., Verrill, S., and Moore, D. H. Two-sample ranktests for
detecting changes thatoccurinasmall proportionofthetreatedpopulation.
Biometrics 43: 641-655 (1987).
43. Conover, W. J., andSalsburg, D. S. Locally mostpowerfultestsfordetec-
ting treatment effects whenonly asubsetofpatients canbeexpected to 're-
spond' to treatment. Biometrics 44: 189-196 (1988).
44. Nation, J. R. Theeffectoforalcadmiumexposureonapassiveavoidance
performance. Toxicol. Let. 20: 41-47 (1984).
45. Cory-Slechta, D. A. Chronicpostweaning leadexposureandresponsedura-
tion performance. Toxicol. Appl. Pharmacol. 60: 78-84 (1981).
46. Hothom, L. Biostatistical analysisofthemicronucleus mutagenicity assay
basedontheassumptionofamixingdistribution. Environ. Health Perspect
102(Suppl 1):121-125 (1994).
47. Unkelbach, H.-D., Deyssenroth, G., Helmstaedter, G., Knappen, F.,
Luedin, E., Mau, J., Passing, H., and Peil, H. Statische Auswertung
haematoligischer andklinisch-chemischer Daten: DerzeitigerStandbei tox-
ikologischen Standardversuchen. In: Biometrie in der chemisch-
pharmazeutischen Industrie, Vol. 1 (J. Xbllmar, Ed.), G. Fischer Verlag,
Stuttgart, 1983, pp. 45-56.
48. Higazi, S. M. F.,andDayton, C. M. Comparingseveralexperimental groups
withacontrol inthemultivariatecase. Commun. Stat. B13: 227-241 (1984).
49. O'Brien, P. C. Procedures forcomparingsamples with multipleendpoints.
Biometrics 40: 1079-1087 (1984).
50. Hothom, L. Multivariatetesting intoxicological studies forcontrolversus
ktreatmentordosegroupsdesign. In: Proceedings ofthe 15thInternational
Biometrics Conference, Budapest, 1990, p. 102.
51. Lehmacher, W., Wassmer, G., andReitmeir, P. Procedures fortwo-sample
comparisons with multiple endpoints controlling theexperimentwise error
rate. Biometrics 47: 511-522 (1991).